AbbVie bows to pressure to keep cheaper Imbruvica formula on the market

16th May 2018 Uncategorised 0

When AbbVie rolled out a single-tablet formulation of its blood cancer drug Imbruvica earlier this year, it pitched the pill to doctors and patients as a convenience. But that convenience came with a hefty price tag—the cost of the smallest dose tripled in price—and that didn’t go over well.

More: AbbVie bows to pressure to keep cheaper Imbruvica formula on the market
Source: fierce